Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

NCT01972763 is registered in ClinicalTrials.gov with Northern California Retina Vitreous Associates as lead sponsor.

NCT NCT01972763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01972763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
Lead sponsor
Northern California Retina Vitreous Associates
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2013
Completion date
July 31, 2018
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recalcitrant wet age-related macular degeneration